Biocon Biologics gains market access coverage for Yesintek in the US
Yesintek is a biosimilar to Stelara (ustekinumab) and is approved for the treatment of Crohn’s disease, ulcerative colitis, plaque…
Sign in
Sign in
Recover your password.
A password will be e-mailed to you.
Browsing Tag
ustekinumab
Biocon Biologics announces positive results from Phase 3 Study of Yesintek biosimilar to Ustekinumab…
The safety profile of YESINTEK was similar to the reference product Stelara (Ustekinumab) throughout the duration of the study
Type 1 diabetes market to reach $9.9 bn in 7MM by 2033
GlobalData’s latest report reveals that the US market is the largest T1D market in the 7MM, accounting for 80.4 per cent of global…
Biocon Biologics gets US market entry date for Bmab 1200, a proposed biosimilar to Stelara
Stelara (Ustekinumab) has been approved for the treatment of psoriasis, Crohn’s disease, ulcerative colitis, plaque psoriasis and…
Janssen presents five year data of STELARA in treatment of Crohn’s Disease
Over half of the patients with moderately to severely active CD who were randomised to subcutaneous ustekinumab every eight weeks…